Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Income from Continuing Operations of 996000.0 for Q1 2026, up 96.12% year-over-year from 507848.85 in Q1 2025, and up 93.26% quarter-over-quarter from 14780000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Income from Continuing Operations data on file, last reported at 996000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 996000.0, up 96.12% year-over-year; the trailing twelve-month figure through Mar 2026 was 24227000.0 (up 86.35% YoY), and the FY2025 annual result was 48911000.0, up 75.19% from the prior year.
- Income from Continuing Operations grew to 996000.0 in Q1 2026 per LXRX's latest filing, from 14780000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3736000.0 in Q2 2025 and troughed at 63693000.0 in Q3 2024.
- A 5-year average of 31176058.82 and a median of 31381000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 123.42% in 2023, then surged 106.75% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 31381000.0 in 2022, then plunged by 48.93% to 46737000.0 in 2023, then gained by 29.95% to 32737000.0 in 2024, then jumped by 54.85% to 14780000.0 in 2025, then jumped by 93.26% to 996000.0 in 2026.
- Business Quant data shows LXRX's Income from Continuing Operations at 996000.0 in Q1 2026, 14780000.0 in Q4 2025, and 12187000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -996,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -996,000.00 |
| Dec 31, 2025 | -14.78 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | -25.68 Mn |
| Dec 31, 2024 | -32.74 Mn |
| Sep 30, 2024 | -63.69 Mn |
| Jun 30, 2024 | -55.35 Mn |
| Mar 31, 2024 | -45.33 Mn |
| Dec 31, 2023 | -46.74 Mn |
| Sep 30, 2023 | -53.53 Mn |
| Jun 30, 2023 | -46.20 Mn |
| Mar 31, 2023 | -32.96 Mn |
| Dec 31, 2022 | -31.38 Mn |
| Sep 30, 2022 | -23.96 Mn |
| Jun 30, 2022 | -24.71 Mn |
| Mar 31, 2022 | -23.49 Mn |
| Dec 31, 2021 | -25.63 Mn |
| Sep 30, 2021 | -23.13 Mn |
| Jun 30, 2021 | -18.13 Mn |